‘Allround Doctors’ Secures 7 Billion KRW Series A Funding

Digital Healthcare Startup

Digital medical device developer Allround Doctors announced on the 6th that it has secured 7 billion KRW in Series A funding.

This investment involved domestic venture capitalists (VCs) including existing investor Aeon Investment, as well as UTC Investment, Futureplay, Korea Investment Partners, and KB Investment.

Allround Doctors, a digital healthcare startup, is the only company in the Asian market developing digital medical devices for cancer patients. It plans to conduct clinical trials within the year for ‘CANMORE,’ a device designed to improve chemotherapy adherence and enhance the quality of life for breast cancer patients undergoing chemotherapy.

Based on CANMORE, Allround Doctors developed ‘CANMORE PRO,’ clinical trial software for monitoring chemotherapy side effects, and has started commercial services. In May, it received approval from global pharmaceutical companies Daiichi Sankyo and AstraZeneca to provide services for clinical trials of the blockbuster immuno-oncology drug Enhertu at Yonsei Cancer Hospital and over ten university hospitals.

For the development of technology that links and calibrates cancer patients’ chemotherapy side effect symptoms with wearable device data (RWD), the company utilized the open-source project ‘Samsung Health Stack’ led by Samsung Electronics. This was also showcased as a case study at the annual Samsung Developer Conference held in the United States.

Through this funding round, Allround Doctors plans to focus on the medical safety and technological advancement of CANMORE, conduct clinical trials under the IRB of the Ministry of Food and Drug Safety within the year, and prepare for full-scale entry into the Japanese market through collaboration with Japan’s largest pharmaceutical development and manufacturing support company.

Jonghyun Lee, CEO of Aeon Investment, said, “Allround Doctors is a rapidly growing team formed by internal medicine specialists and IT developers working together. Along with the development of digital medical devices to improve medication adherence for breast cancer patients, we also expect the clinical effectiveness of ‘cancer survivor-centered personalized healthcare technology,’ which is currently under research, development, and clinical trials with national and regional cancer centers.”

Sungdong Kwak, CEO of Allround Doctors, stated, “Currently, in South Korea, the management of chemotherapy side effects for cancer patients is not supported by medical fees, causing inconvenience for both patients and doctors. In Europe, patient self-reporting is being presented as a guideline by the largest oncology society, and self-monitoring and management are becoming standardized, with active discussions on medical fees underway. With this investment, we aim to achieve the medical safety and technological advancement goals of CANMORE in collaboration with domestic oncology medical staff.”